Generative AI for life sciences
RAPPORT
CONSUMER

Generative AI for life sciences

Capgemini Group expects GenAI to evolve rapidly over the next few years and has identified three phases of this evolution. Is your marketing primed to take advantage of the GenAI technology? Download our latest point of view on the topic: to get the fundamentals right.

Generative AI (GenAI) is poised to deliver a dose of adrenalin that will
revolutionize the life sciences industry. But just as companies must design
clinical trials to ensure accuracy,legitimacy, and efficacy, they must
also carefully manage the deployment of GenAI throughout the enterprise.

At Capgemini Group, we believe this technology will evolve rapidly over the next few years and have identified three phases of this evolution – exploration, augmentation, and re-invention. Now is the time for organizations to plan their generative AI strategy and explore carefully selected use cases in a controlled environment.

Free download

By submitting this form, I understand that my data will be processed by Sogeti as described in the Privacy Notice.

CONTACT
  • Therese Sinter
    Therese Sinter
    Marketing & Communications Director, Sogeti Nordics
    +46 70 361 46 21

    Sorry, this content can only be visible if Functional Cookies are accepted. Please go to the Cookie Settings and change your preferences.